Price movement over the last 24 hours
Abbott Laboratories vs Global X SuperDividend ETF — how do they compare? Abbott Laboratories trades at $95.4 (market cap $166.94B), while Global X SuperDividend ETF trades at $24.3. The key difference: Abbott Laboratories pays a 2.63% dividend while Global X SuperDividend ETF pays none, and Global X SuperDividend ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | SDIV | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $26.34 |
52-Week Low | $82.57 | $22.90 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SDIV trades at $24.46, down 0.37% on the day, with a bullish technical signal driven by strong buy indicators despite bearish moving averages. The ETF offers a high dividend yield, recently paying $0.18 per share quarterly, attracting income-focused investors. Recent news highlights its role in diversified portfolios for retirees seeking steady cash flow, with a current yield around 9%.
Outlook is supported by yield appeal in a higher-rate environment, but risks include sensitivity to interest rates and limited tech exposure. Analysts view it as a diversification tool amid AI sector concentration, though valuation metrics are not fully disclosed. Institutional activity shows mixed signals with recent buying and selling.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →